VivoSeq
Other

Scopolamine

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Scopolamine is an early-stage landscape with 0 programs across 3 companies. The most active players are Repurposed Therapeutics, Inc., Pfizer, GSK.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

45/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Repurposed Therapeutics, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%
Terminated4 · 36%
Unknown status1 · 9%
Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

Effects of Transdermal Scopolamine on Occupational Performance
Completed·—·Phase 2·NCT00374478·33 enrolled
Nebulizer Delivery of Intranasal Scopolamine
Completed·—·Phase 1·NCT04999449·14 enrolled
Scopolamine Patch Pharmacokinetics in Healthy Adults
Completed·UUniversity of Iowa·Phase 4·NCT03029650·26 enrolled
Scopolamine Challenge Study
Completed·Pfizer logoPfizer·Phase 1·NCT01213355·38 enrolled
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
Completed·GSK logoGSK·Phase 1·NCT02839135·128 enrolled
The Antidepressant Efficacy of the Anticholinergic Scopolamine
Terminated·National Institute of Mental Health (NIMH)·Phase 2·NCT00369915·17 enrolled
A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
Terminated·MMassachusetts General Hospital·Phase 2·NCT01312844·7 enrolled
A Study to Evaluate the Intramuscular Administration of Scopolamine
Terminated·BBattelle Memorial Institute·Phase 1·NCT04314713·32 enrolled
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
Terminated·RRepurposed Therapeutics, Inc.·Phase 2/3·NCT02155309·63 enrolled
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
Withdrawn·YYale University·Phase 1·NCT06014385
Scopolamine in Healthy Volunteers
Unknown status·RRepurposed Therapeutics, Inc.·Phase 1·NCT03874130·130 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)